Morgan Stanley Downgrades Alpine Immune Sciences to Equal-Weight, Raises Price Target to $65
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Michael Ulz downgraded Alpine Immune Sciences (ALPN) from Overweight to Equal-Weight but raised the price target from $47 to $65.

April 11, 2024 | 9:46 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Alpine Immune Sciences was downgraded by Morgan Stanley from Overweight to Equal-Weight, though its price target was increased from $47 to $65.
The downgrade to Equal-Weight suggests a neutral outlook on ALPN's stock, indicating that it might perform in line with the market. However, the increase in the price target to $65 from $47 reflects a positive adjustment in the expected stock value, suggesting underlying optimism about the company's fundamentals or growth prospects. This mixed signal could lead to short-term uncertainty among investors as they weigh the downgrade against the higher price target.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100